investigator_user investigator user funding collaborators pending menu bell message arrow_up arrow_down filter layers globe marker add arrow close download edit facebook info linkedin minus plus save share search sort twitter remove user-plus user-minus
  • Project leads
  • Collaborators

Targeting Drug-Insensitive CML Stem Cells with Combination Therapy of New ABL and PP2A Inhibitors

Xiaoyan Jiang

0 Collaborator(s)

Funding source

Canadian Institutes of Health Research (CIHR)

Xiaoyan Jiang

BC Cancer Agency

Vancouver, Canada

Related projects

Robert M Williams

Multiple Myeloma and Cancer Therapies via Largazole Analogs

Leukaemia

Pathology Hematology and hematologic malignancies

Breanne Landry

A New Approach for Acute Myeloid Leukemia Treatment: siRNA Nanoparticles to Turn-Off Infinite Proliferation and Evasion of Apoptosis

Leukaemia

Li Zhang

A new cellular immunotherapy to treat acute myeloid leukemia

Leukaemia

Matthew H Porteus

Pre-Clinical Development of Nuclease Mediated Gene Therapy for SCID

Leukaemia

Tak Mak

CRC Tier 1 - Determining why mutations of the metabolic enzyme isocitrate dehydrogenase cause leukemias and brain cancers

Leukaemia Brain, nervous system

Jerald Patrick Radich

The Genetics of Post-Transplant Relapse in Myeloid Malignancy

Leukaemia

Pathology

Investigator from Institut d'Investigació Biomédica de Bellvitge

Deciphering PI3K biology in health and disease

Leukaemia

Andrew Weng

Adult vs. Fetal Programs in Leukemia Pathogenesis

Leukaemia

Pathology Pediatric oncology or childhood cancer

Nkiru Odunukwe

National Multiple Myeloma Survey: Prevalence and Treatment Outcomes in Nigeria

Leukaemia

Hematology and hematologic malignancies